Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Income from Continuing Operations (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Income from Continuing Operations for 16 consecutive years, with 4132000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 42.44% to 4132000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 17382000.0 through Dec 2025, up 103.3% year-over-year, with the annual reading at 17382000.0 for FY2025, 103.3% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 4132000.0 at Niagen Bioscience, down from 4578000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 7179000.0 in Q4 2024, with the low at 8856000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 1242550.0, with a median of 1201500.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations tumbled 110.11% in 2021, then soared 24160.0% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 5325000.0 in 2021, then skyrocketed by 72.88% to 1444000.0 in 2022, then skyrocketed by 107.89% to 114000.0 in 2023, then skyrocketed by 6197.37% to 7179000.0 in 2024, then plummeted by 42.44% to 4132000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 4132000.0, 4578000.0, and 3609000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.